Oktay Gülcü
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Oktay Gülcü has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Emrah Aksakal
Department of Cardiology, University of Health Sciences, Erzurum City Hospital, Erzurum, Turkey
6 shared publications - Kamuran Kalkan
Department of Cardiology, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara 06800, Türkiye
6 shared publications - İbRahim Sarac
ATATÜRK ÜNİVERSİTESİ, TIP FAKÜLTESİ
4 shared publications - Selim Aydemir
Department of Cardiology, University of Health Sciences, Erzurum City Hospital, Erzurum, Turkey
4 shared publications - Sidar Şiyar Aydın
Department of Cardiology, Ataturk University Faculty of Medicine, Erzurum, Turkey
4 shared publications - Faruk Aydınyılmaz
Department of Cardiology, University of Health Sciences, Erzurum Bolge Training and Research Hospital, Yakutiye/Erzurum, Türkiye
3 shared publications
Latest Publications
- Open Access
Admission Laboratory-Based Prediction of Six-Month Mortality After COVID-19 Hospitalization: Model Development, Bootstrap Internal Validation, and Single-Center Temporal Validation
Background and Objectives: Early identification of patients at high risk of death after COVID-19 hospitalization may support monitoring, follow-up planning and resource allocation. We aimed to develop and internally validate a parsimonious admission laboratory-based model for six-month all-cause mortality and derive a simplified risk score. Materials and Methods: This retrospective single-center cohort included 1827 consecutive adults hospitalized with COVID-19 between 3 March and 6 November 2020. The primary model was developed in 1559 patients with complete predictor data after data-quality review. Prespecified predictors were age, albumin, neutrophil-to-lymphocyte ratio, blood urea nitrogen, lactate dehydrogenase, troponin I and sodium. Model performance was assessed using discrimination and calibration measures, 500-sample bootstrap internal validation and a chronological split-sample assessment in later admissions from the same center; this was internal–temporal rather than external validation. The simplified score was derived exclusively in the chronological development cohort and applied unchanged to the later cohort. Results: Among 1827 eligible patients, 437 died within six months (23.9%). The primary complete-case modeling cohort included 1559 patients, of whom 386 died. Older age, lower albumin and higher neutrophil-to-lymphocyte ratio, blood urea nitrogen, lactate dehydrogenase, troponin I and sodium were independently associated with mortality. The model achieved an apparent AUC of 0.936 (95% CI 0.919–0.954) and an optimism-corrected AUC of 0.933. The later same-center cohort yielded an AUC of 0.908 (95% CI 0.871–0.939). The development-derived simplified score had an AUC of 0.927 (95% CI 0.909–0.943) in the development cohort and 0.916 (95% CI 0.885–0.944) when applied unchanged to the later cohort. Conclusions: A model combining age with six routinely available admission laboratory variables showed strong discrimination for six-month all-cause mortality after COVID-19 hospitalization and retained good discrimination in single-center temporal assessment. However, calibration drift was observed, and the model and simplified score should currently be considered supportive risk-stratification frameworks rather than deployable stand-alone clinical calculators. External validation, contemporary recalibration and prospective assessment of clinical utility are required before implementation.
Open AccessAdmission Laboratory-Based Prediction of Six-Month Mortality After COVID-19 Hospitalization: Model Development, Bootstrap Internal Validation, and Single-Center Temporal Validation
Background and Objectives: Early identification of patients at high risk of death after COVID-19 hospitalization may support monitoring, follow-up planning and resource allocation. We aimed to develop and internally validate a parsimonious admission laboratory-based model for six-month all-cause mortality and derive a simplified risk score. Materials and Methods: This retrospective single-center cohort included 1827 consecutive adults hospitalized with COVID-19 between 3 March and 6 November 2020. The primary model was developed in 1559 patients with complete predictor data after data-quality review. Prespecified predictors were age, albumin, neutrophil-to-lymphocyte ratio, blood urea nitrogen, lactate dehydrogenase, troponin I and sodium. Model performance was assessed using discrimination and calibration measures, 500-sample bootstrap internal validation and a chronological split-sample assessment in later admissions from the same center; this was internal–temporal rather than external validation. The simplified score was derived exclusively in the chronological development cohort and applied unchanged to the later cohort. Results: Among 1827 eligible patients, 437 died within six months (23.9%). The primary complete-case modeling cohort included 1559 patients, of whom 386 died. Older age, lower albumin and higher neutrophil-to-lymphocyte ratio, blood urea nitrogen, lactate dehydrogenase, troponin I and sodium were independently associated with mortality. The model achieved an apparent AUC of 0.936 (95% CI 0.919–0.954) and an optimism-corrected AUC of 0.933. The later same-center cohort yielded an AUC of 0.908 (95% CI 0.871–0.939). The development-derived simplified score had an AUC of 0.927 (95% CI 0.909–0.943) in the development cohort and 0.916 (95% CI 0.885–0.944) when applied unchanged to the later cohort. Conclusions: A model combining age with six routinely available admission laboratory variables showed strong discrimination for six-month all-cause mortality after COVID-19 hospitalization and retained good discrimination in single-center temporal assessment. However, calibration drift was observed, and the model and simplified score should currently be considered supportive risk-stratification frameworks rather than deployable stand-alone clinical calculators. External validation, contemporary recalibration and prospective assessment of clinical utility are required before implementation.
- 22 September 2024
- Published by Acil Tip Uzmanlari Dernegi in Journal of Emergency Medicine Case Reports
- Vol. 15 (3) , 77-79
A Case of Takotsubo Cardiomyopathy
Takotsubo cardiomyopathy (TCM), also called stress cardiomyopathy, broken heart syndrome and apical ballooning syndrome, is a heart problem that occurs after intense stress, sadness or shock. Takotsubo cardiomyopathy usually presents with chest pain and dyspnoea and is similar to the diagnosis of acute coronary syndrome. Echocardiography and coronary angiography have an important role in the diagnosis of Takotsubo cardiomyopathy. In this case report, we wanted to investigate Takotsubo cardiomyopathy in a 59-year-old woman who presented to the emergency department.
- 22 September 2024
- Published by Acil Tip Uzmanlari Dernegi in Journal of Emergency Medicine Case Reports
- Vol. 15 (3) , 77-79
A Case of Takotsubo Cardiomyopathy
Takotsubo cardiomyopathy (TCM), also called stress cardiomyopathy, broken heart syndrome and apical ballooning syndrome, is a heart problem that occurs after intense stress, sadness or shock. Takotsubo cardiomyopathy usually presents with chest pain and dyspnoea and is similar to the diagnosis of acute coronary syndrome. Echocardiography and coronary angiography have an important role in the diagnosis of Takotsubo cardiomyopathy. In this case report, we wanted to investigate Takotsubo cardiomyopathy in a 59-year-old woman who presented to the emergency department.
- 1 November 2023
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 17 (21) , 899-906
Relationship between Platelet/Hemoglobin and Radial Thrombus in Patients with Coronary Angiography Via Radial Access
Aim: To predict the development of radial artery thrombus (RAT) in patients with radial approach coronary angiography of platelet-to-hemoglobin ratio (PHR). Materials & methods: This study was desi...
- 1 November 2023
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 17 (21) , 899-906
Relationship between Platelet/Hemoglobin and Radial Thrombus in Patients with Coronary Angiography Via Radial Access
Aim: To predict the development of radial artery thrombus (RAT) in patients with radial approach coronary angiography of platelet-to-hemoglobin ratio (PHR). Materials & methods: This study was desi...
- 30 September 2022
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 62 (9) , 67-73
The relationship between pericardial effusion and pulmonary involvement, prognosis, mortality in COVID-19 patients
Aim Comprehensive studies on the coexistence of COVID-19 and pericardial effusion (PEff) are limited. In this study, we investigated the relationship between pneumonia severity and PEff, predisposing factors, and the effect of PEff on clinical prognosis and mortality in COVID-19 patients. Material and methods Between March and November 2020, 5 575 patients were followed up in our pandemic hospital due to COVID-19. 3 794 patients with positive polymerase chain reaction (PCR) test results and thoraxcomputerized tomography (CT) imaging at admission were included in the study. The clinical and demographic characteristics, CT images, hematological and biochemical parameters of these patients were retrospectively examined. Pulmonary involvement of 3794 patients was divided into three groups and its relationship with PEff was investigated retrospectively. Results There were 560 patients who did not have pulmonary involvement, 2 639 patients with pulmonary involvement below 50 %, and 595 patients with 50 % or more pulmonary involvement. As pulmonaryinvolvement or the severity of the disease increased, male gender and advanced age become statistically significant. The mean age of patients with PEff was higher, and PEff was more common in males. Patients with PEff had more comorbid diseases and significantly elevated serum cardiac and inflammatory biomarkers. The need for intensive care and mortality rates were higher in these patients. While the in-hospital mortality rate was 56.9 % in patients with PEff and pulmonary involvement above 50 %, in-hospital mortality rate was 34.4 % in patients with pulmonary involvement above 50 % and without PEff (pConclusion As the severity of pulmonary involvement or the clinical severity of the disease increased, PEff occurred in patients or the degree of PEff increased. The clinical prognosis of patients presenting with PEff was quite poor, and the frequency of intensive care admissions and mortality were significantly higher. PEff was an important finding in the follow-up and management of patients with COVID-19, and it reflected the clinical prognosis.
- 30 September 2022
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 62 (9) , 67-73
The relationship between pericardial effusion and pulmonary involvement, prognosis, mortality in COVID-19 patients
Aim Comprehensive studies on the coexistence of COVID-19 and pericardial effusion (PEff) are limited. In this study, we investigated the relationship between pneumonia severity and PEff, predisposing factors, and the effect of PEff on clinical prognosis and mortality in COVID-19 patients. Material and methods Between March and November 2020, 5 575 patients were followed up in our pandemic hospital due to COVID-19. 3 794 patients with positive polymerase chain reaction (PCR) test results and thoraxcomputerized tomography (CT) imaging at admission were included in the study. The clinical and demographic characteristics, CT images, hematological and biochemical parameters of these patients were retrospectively examined. Pulmonary involvement of 3794 patients was divided into three groups and its relationship with PEff was investigated retrospectively. Results There were 560 patients who did not have pulmonary involvement, 2 639 patients with pulmonary involvement below 50 %, and 595 patients with 50 % or more pulmonary involvement. As pulmonaryinvolvement or the severity of the disease increased, male gender and advanced age become statistically significant. The mean age of patients with PEff was higher, and PEff was more common in males. Patients with PEff had more comorbid diseases and significantly elevated serum cardiac and inflammatory biomarkers. The need for intensive care and mortality rates were higher in these patients. While the in-hospital mortality rate was 56.9 % in patients with PEff and pulmonary involvement above 50 %, in-hospital mortality rate was 34.4 % in patients with pulmonary involvement above 50 % and without PEff (pConclusion As the severity of pulmonary involvement or the clinical severity of the disease increased, PEff occurred in patients or the degree of PEff increased. The clinical prognosis of patients presenting with PEff was quite poor, and the frequency of intensive care admissions and mortality were significantly higher. PEff was an important finding in the follow-up and management of patients with COVID-19, and it reflected the clinical prognosis.
- Open Access
- 7 July 2022
- Published by Springer Nature in The Egyptian Heart Journal
- Vol. 74 (1) , 1-8
Does new onset and pre-existing atrial fibrillation predict mortality in COVID-19 patients?
Background: Coronavirus Disease-2019 (COVID-19), caused by Severe Acute Respiratory Syndrome-Coronavirus-2, still remains prevalent and severe. We aimed to evaluate the effects of pre-existing atrial fibrillation and new-onset atrial fibrillation (NOAF) on the clinical severity and mortality of COVID-19. Results: Between April and December 2020, 5577 patients with positive PCR and/or COVID-19 compatible findings in computed tomography hospitalized were enrolled retrospectively. Total and in-hospital mortality, need for intensive care unit (ICU), need for mechanical ventilation, and recurrent hospitalization results of 286 patients with pre-existing AF before hospitalization and 82 patients with NOAF during hospitalization were evaluated. Preexisting AF was associated with a 2-fold increase in total and in-hospital mortality [OR (2.16 (1.62–2.89), 2.02 (1.48–2.76), P < 0.001, respectively]. NOAF was associated with a 14-fold increase in total mortality and a 12-fold increase in in-hospital mortality [OR(14.72 (9.22–23.5), 12.56 (8.02–19.68), P < 0.001], respectively]. However, pre-existing AF and NOAF resulted in increased ICU admission, mechanical ventilation, and recurrent hospitalization. In the Cox regression analysis, NOAF was observed as an independent risk factor for mortality. Conclusions: Pre-existing AF and in-hospital NOAF were associated with increased mortality and severity in hospitalized COVID-19 patients. In addition, NOAF was observed as an independent prognostic indicator in terms of total mortality.
- 7 July 2022
- Published by Springer Nature in The Egyptian Heart Journal
- Vol. 74 (1) , 1-8
Open AccessDoes new onset and pre-existing atrial fibrillation predict mortality in COVID-19 patients?
Background: Coronavirus Disease-2019 (COVID-19), caused by Severe Acute Respiratory Syndrome-Coronavirus-2, still remains prevalent and severe. We aimed to evaluate the effects of pre-existing atrial fibrillation and new-onset atrial fibrillation (NOAF) on the clinical severity and mortality of COVID-19. Results: Between April and December 2020, 5577 patients with positive PCR and/or COVID-19 compatible findings in computed tomography hospitalized were enrolled retrospectively. Total and in-hospital mortality, need for intensive care unit (ICU), need for mechanical ventilation, and recurrent hospitalization results of 286 patients with pre-existing AF before hospitalization and 82 patients with NOAF during hospitalization were evaluated. Preexisting AF was associated with a 2-fold increase in total and in-hospital mortality [OR (2.16 (1.62–2.89), 2.02 (1.48–2.76), P < 0.001, respectively]. NOAF was associated with a 14-fold increase in total mortality and a 12-fold increase in in-hospital mortality [OR(14.72 (9.22–23.5), 12.56 (8.02–19.68), P < 0.001], respectively]. However, pre-existing AF and NOAF resulted in increased ICU admission, mechanical ventilation, and recurrent hospitalization. In the Cox regression analysis, NOAF was observed as an independent risk factor for mortality. Conclusions: Pre-existing AF and in-hospital NOAF were associated with increased mortality and severity in hospitalized COVID-19 patients. In addition, NOAF was observed as an independent prognostic indicator in terms of total mortality.
- Open Access
- 1 June 2022
- Published by AVES YAYINCILIK A.Ş. in The Eurasian Journal of Medicine
- Vol. 54 (2) , 145-149
The Relationship Between Clinical Outcomes and Calculated Thrombus Burden Before and After Initial Flow in Patients with ST-Segment Elevation Myocardial Infarction
Objective: Primary percutaneous coronary intervention is the standard treatment for ST-segment eleva- tion myocardial infarction. Although myocardial and epicardial perfusion is usually achieved with primary percutaneous coronary intervention, infarct-related arterial thrombus burden negatively affects the proce- dural success and clinical outcomes of primary percutaneous coronary intervention. Therefore, we aimed to investigate the association between thrombus burden (calculated before and after initial flow) and clinical consequences in patients with ST-segment elevation myocardial infarction. Materials and Methods: This study retrospectively enrolled 1376 patients who had ST-segment elevation myo- cardial infarction between May 2012 and November 2015. Patients who had only undergone balloon angio- plasty and emergency coronary artery bypass grafting were not included in the study. Data regarding the initial clinical and demographic features of the patients were obtained from their hospital records. Thrombus burden was calculated using baseline and final (after wire inflation or small balloon dilatation) thrombolysis in myocardial infarction thrombus grades. The endpoints of the study were defined as no-reflow development after primary percutaneous coronary intervention and 1-year all-cause mortality. Statistical significance was defined as P < .05. Results: No-reflow was detected in 169 patients (12.3%). The calculated basal thrombus burden was signifi- cantly associated with post-procedural no-reflow (P < .001). No-reflow was also associated with advanced age (P < .001), longer pain-to-door time (P < .001), and increased blood glucose levels (P = .032). The calcu- lated final thrombus burden was related to 1-year all-cause mortality (P = .047). One-year all-cause mortality was also associated with advanced age (P < .001), high Killip scores (P=.003), increased white blood cell counts (P = .001), and low estimated glomerular filtration rates (P < .001). Conclusion: Basal thrombus burden was associated with no-reflow, and final thrombus burden was associ- ated with 1-year all-cause mortality. The calculation of thrombus burden before and after initial flow may help to predict clinical outcomes. Cite this article as: Birdal O, Topçu S, Tanboğa IH, et al. The relationship between clinical outcomes and calculated thrombus burden before and after initial flow in patients with ST-segment elevation myocardial infarction. Eurasian J Med 2022;54(2):145-149.
- 1 June 2022
- Published by AVES YAYINCILIK A.Ş. in The Eurasian Journal of Medicine
- Vol. 54 (2) , 145-149
Open AccessThe Relationship Between Clinical Outcomes and Calculated Thrombus Burden Before and After Initial Flow in Patients with ST-Segment Elevation Myocardial Infarction
Objective: Primary percutaneous coronary intervention is the standard treatment for ST-segment eleva- tion myocardial infarction. Although myocardial and epicardial perfusion is usually achieved with primary percutaneous coronary intervention, infarct-related arterial thrombus burden negatively affects the proce- dural success and clinical outcomes of primary percutaneous coronary intervention. Therefore, we aimed to investigate the association between thrombus burden (calculated before and after initial flow) and clinical consequences in patients with ST-segment elevation myocardial infarction. Materials and Methods: This study retrospectively enrolled 1376 patients who had ST-segment elevation myo- cardial infarction between May 2012 and November 2015. Patients who had only undergone balloon angio- plasty and emergency coronary artery bypass grafting were not included in the study. Data regarding the initial clinical and demographic features of the patients were obtained from their hospital records. Thrombus burden was calculated using baseline and final (after wire inflation or small balloon dilatation) thrombolysis in myocardial infarction thrombus grades. The endpoints of the study were defined as no-reflow development after primary percutaneous coronary intervention and 1-year all-cause mortality. Statistical significance was defined as P < .05. Results: No-reflow was detected in 169 patients (12.3%). The calculated basal thrombus burden was signifi- cantly associated with post-procedural no-reflow (P < .001). No-reflow was also associated with advanced age (P < .001), longer pain-to-door time (P < .001), and increased blood glucose levels (P = .032). The calcu- lated final thrombus burden was related to 1-year all-cause mortality (P = .047). One-year all-cause mortality was also associated with advanced age (P < .001), high Killip scores (P=.003), increased white blood cell counts (P = .001), and low estimated glomerular filtration rates (P < .001). Conclusion: Basal thrombus burden was associated with no-reflow, and final thrombus burden was associ- ated with 1-year all-cause mortality. The calculation of thrombus burden before and after initial flow may help to predict clinical outcomes. Cite this article as: Birdal O, Topçu S, Tanboğa IH, et al. The relationship between clinical outcomes and calculated thrombus burden before and after initial flow in patients with ST-segment elevation myocardial infarction. Eurasian J Med 2022;54(2):145-149.
- Open Access
- 1 January 2022
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 79 (10) , 963-969
The evaluation of epicardial adipose tissue and carotid intima-media thickness in patients with Behçet’s disease
Background/Aim. Epidemiological studies indicate that cardiovascular disease (CVD) is common in almost all patients diagnosed with autoimmune disease. This study aimed to examine whether epicardial adipose tissue (EAT) thickness (EATT) and carotid intima-media (CIM) thickness (CIMT) differ between patients with Beh?et?s disease (BD) and healthy individuals. Methods. A total of 40 healthy subjects as controls and 40 BD patients with musculoskeletal complaints were enrolled in this cross-sectional prospective study. Socio-demographic, clinical, and laboratory data were obtained and compared between groups. The Beh?et?s Disease Current Activity Form was used to assess disease activity. Both groups underwent echocardiography in order to measure EATT and CIMT. Results. The mean thickness of EAT (5.70 ? 1.05 mm; 2.50 ? 0.61 mm, respectively, p < 0.001) and CIM (0.68 ? 0.05 mm; 0.63 ? 0.06 mm, respectively, p = 0.002) were significantly in-creased in BD patients compared to the control group. A positive correlation was observed between EATT and age (r = 0.500, p = 0.001), the duration of the disease (r = 0.330, p < 0.001), waist circumference (r = 0.316, p = 0.013), and disease activity (r = 0.31, p < 0.001) in the patient group. CIMT was positively correlated with age (r = 0.594, p = 0.001) and the duration of the disease (r = 0.585, p = 0.001). The use of glucocorticoids or clinical manifestations (joint involvements, genital ulcer, skin lesions, inflammatory back pain, and major organ involvement) of the patients were not found to be associated with EATT or CIMT. Conclusion. EATT and CIMT are in-creased in patients with BD and are associated with dis-ease activity. Echocardiographic measurement of EATT and CIMT is an objective, noninvasive, and available method that can evaluate the risk of subclinical atherosclerosis in patients with BD.
- 1 January 2022
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 79 (10) , 963-969
Open AccessThe evaluation of epicardial adipose tissue and carotid intima-media thickness in patients with Behçet’s disease
Background/Aim. Epidemiological studies indicate that cardiovascular disease (CVD) is common in almost all patients diagnosed with autoimmune disease. This study aimed to examine whether epicardial adipose tissue (EAT) thickness (EATT) and carotid intima-media (CIM) thickness (CIMT) differ between patients with Beh?et?s disease (BD) and healthy individuals. Methods. A total of 40 healthy subjects as controls and 40 BD patients with musculoskeletal complaints were enrolled in this cross-sectional prospective study. Socio-demographic, clinical, and laboratory data were obtained and compared between groups. The Beh?et?s Disease Current Activity Form was used to assess disease activity. Both groups underwent echocardiography in order to measure EATT and CIMT. Results. The mean thickness of EAT (5.70 ? 1.05 mm; 2.50 ? 0.61 mm, respectively, p < 0.001) and CIM (0.68 ? 0.05 mm; 0.63 ? 0.06 mm, respectively, p = 0.002) were significantly in-creased in BD patients compared to the control group. A positive correlation was observed between EATT and age (r = 0.500, p = 0.001), the duration of the disease (r = 0.330, p < 0.001), waist circumference (r = 0.316, p = 0.013), and disease activity (r = 0.31, p < 0.001) in the patient group. CIMT was positively correlated with age (r = 0.594, p = 0.001) and the duration of the disease (r = 0.585, p = 0.001). The use of glucocorticoids or clinical manifestations (joint involvements, genital ulcer, skin lesions, inflammatory back pain, and major organ involvement) of the patients were not found to be associated with EATT or CIMT. Conclusion. EATT and CIMT are in-creased in patients with BD and are associated with dis-ease activity. Echocardiographic measurement of EATT and CIMT is an objective, noninvasive, and available method that can evaluate the risk of subclinical atherosclerosis in patients with BD.
- 2 June 2021
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 53 (1) , 88-95
Association between previous anticoagulant use and mortality among hospitalized patients with COVID-19
Although COVID-19 disease primarily affects the respiratory system, it has been seen in many studies that it causes thromboembolic (TE) events in many tissues and organs. So that, to prevent TE can reduce mortality and morbidity. In this context, this study aimed to investigate the relationship between the previous use of warfarin or other new direct oral anticoagulants (OAC) and mortality in patients hospitalized with a diagnosis of COVID-19 before hospitalization. A total of 5575 patients who were diagnosed with COVID-19 were hospitalized and started treatment between March 21 and November 30, 2020 were included in the study. The primary outcome was in-hospital all-cause mortality. A retrospective cohort study design was planned. Patients were followed up until death or censoring on November 30, 2020. The candidate predictors for primary outcome should be clinically and biologically plausible, and their relationships with all-cause death should be demonstrated in previous studies. We considered all candidate predictors included in the model in accordance with these principles. The main candidate predictor was previous OAC use. The primary analysis method was to compare the time to deaths of patients using and not using previous OAC by a multivariable Cox proportional hazard model (CPHM). In the CPHM, previous OAC use was found to be associated with a significantly lower mortality risk (adjusted hazard ratio 0.62, 95% CI 0.42–0.92, p = 0.030). In hospitalized COVID-19 patients, in patients who previously used anticoagulantswas associated with lower risk of in-hospital death than in those who did not.
- 2 June 2021
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 53 (1) , 88-95
Association between previous anticoagulant use and mortality among hospitalized patients with COVID-19
Although COVID-19 disease primarily affects the respiratory system, it has been seen in many studies that it causes thromboembolic (TE) events in many tissues and organs. So that, to prevent TE can reduce mortality and morbidity. In this context, this study aimed to investigate the relationship between the previous use of warfarin or other new direct oral anticoagulants (OAC) and mortality in patients hospitalized with a diagnosis of COVID-19 before hospitalization. A total of 5575 patients who were diagnosed with COVID-19 were hospitalized and started treatment between March 21 and November 30, 2020 were included in the study. The primary outcome was in-hospital all-cause mortality. A retrospective cohort study design was planned. Patients were followed up until death or censoring on November 30, 2020. The candidate predictors for primary outcome should be clinically and biologically plausible, and their relationships with all-cause death should be demonstrated in previous studies. We considered all candidate predictors included in the model in accordance with these principles. The main candidate predictor was previous OAC use. The primary analysis method was to compare the time to deaths of patients using and not using previous OAC by a multivariable Cox proportional hazard model (CPHM). In the CPHM, previous OAC use was found to be associated with a significantly lower mortality risk (adjusted hazard ratio 0.62, 95% CI 0.42–0.92, p = 0.030). In hospitalized COVID-19 patients, in patients who previously used anticoagulantswas associated with lower risk of in-hospital death than in those who did not.
- Open Access
- 1 January 2021
- Published by ScopeMed in Medicine Science | International Medical Journal
- Vol. 10 (3) , 714
Macro-CK in carbon monoxide poisoning: A guide for in-hospital mortality?
- 1 January 2021
- Published by ScopeMed in Medicine Science | International Medical Journal
- Vol. 10 (3) , 714
Open AccessMacro-CK in carbon monoxide poisoning: A guide for in-hospital mortality?
- Open Access
- 29 November 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (12) , 3797
A Novel Marker of Inflammation: Azurocidin in Patients with ST Segment Elevation Myocardial Infarction
(1) To investigate the role of azurocidin, an antimicrobial protein, in patients with ST segment elevation myocardial infarction (STEMI). (2) This single-center prospective observational study included patients with STEMI and healthy age- and sex-matched control subjects. Baseline demographic, clinical and biochemical data were compared between the two groups. Azurocidin levels at baseline were determined using an enzyme-linked immunosorbent assay. Multivariate linear regression analysis with enter method was used to test the association between azurocidin and independent variables, such as the thrombolysis in myocardial infarction (TIMI) score, synergy between percutaneous coronary intervention with TAXUS and cardiac surgery score, global registry of acute coronary events score, Killip class, C-reactive protein (CRP), and creatinine kinase-myocardial band (CK-MB). (3) A total of 76 patients with STEMI and 30 healthy control subjects were enrolled in the study. Mean ± SD azurocidin levels were significantly higher in patients compared with healthy controls (18.07 ± 13.99 versus 10.09 ± 5.29 ng/mL, respectively). In a receiver-operating characteristic curve analysis, an azurocidin cut-off level of >11.46 ng/mL had 74% sensitivity and 58% specificity in predicting myocardial infarction. Azurocidin levels had a positive correlation with TIMI score (r = 0.651). In multivariate linear regression analysis, the TIMI score was an independent predictor of the azurocidin level. (4) Azurocidin is an infection marker that may be important in patients with STEMI.
- 29 November 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (12) , 3797
Open AccessA Novel Marker of Inflammation: Azurocidin in Patients with ST Segment Elevation Myocardial Infarction
(1) To investigate the role of azurocidin, an antimicrobial protein, in patients with ST segment elevation myocardial infarction (STEMI). (2) This single-center prospective observational study included patients with STEMI and healthy age- and sex-matched control subjects. Baseline demographic, clinical and biochemical data were compared between the two groups. Azurocidin levels at baseline were determined using an enzyme-linked immunosorbent assay. Multivariate linear regression analysis with enter method was used to test the association between azurocidin and independent variables, such as the thrombolysis in myocardial infarction (TIMI) score, synergy between percutaneous coronary intervention with TAXUS and cardiac surgery score, global registry of acute coronary events score, Killip class, C-reactive protein (CRP), and creatinine kinase-myocardial band (CK-MB). (3) A total of 76 patients with STEMI and 30 healthy control subjects were enrolled in the study. Mean ± SD azurocidin levels were significantly higher in patients compared with healthy controls (18.07 ± 13.99 versus 10.09 ± 5.29 ng/mL, respectively). In a receiver-operating characteristic curve analysis, an azurocidin cut-off level of >11.46 ng/mL had 74% sensitivity and 58% specificity in predicting myocardial infarction. Azurocidin levels had a positive correlation with TIMI score (r = 0.651). In multivariate linear regression analysis, the TIMI score was an independent predictor of the azurocidin level. (4) Azurocidin is an infection marker that may be important in patients with STEMI.